Selectivity of site of action and systemic effects of topical alpha agonists

Current Opinion in Ophthalmology

Volumn 9, Issue 2, 1998, Pages 30-33

  Robin, Alan L ^a,b,c   Burnstein, Yochanan ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BRIMONIDINE; CLONIDINE;

BLOOD DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG MECHANISM; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; GLAUCOMA; OPTIC NERVE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0031778983     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199804000-00006     Document Type: Review

References (24)

1. Mittag TW, Tormay A: Drug responses of adenylate cyclase in iris ciliary body determined by adenine labeling. Invest Ophthalmol Vis Sci 1985, 26:39-40.
2. Toris CB, Tafoya MF, Camras CB, Yablonski ME: Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995, 102:456-461.
3. Abrams DA, et al.: A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure. Am J Ophthalmol 1989, 108:230.,
4. Toris CB, Fleason ML, Camras CB, Yablonski ME: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995, 113:1514-1517.
5. Kharlamb AB, Burke JA, Runde EK: I-1 Imidazoline receptor subtype mediates ocular hypotensive and cardiovascular effects of brimonidine in cynomolgus monkeys [abstract]. Invest Ophthalmol Vis Sci 1994, 35:2048.
6. Burke J, Schwartz M: Preclinical evaluation of brimonidine. Surv Ophthalmol 1996, 41(S):S9-S18.
7. Maier C, Steinberg GK, Sun GH, et al.: Neuroprotection by the alpha-2 adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993, 798:306-312.
8. Robin AL: Short term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988, 106:912.
9. Derick RJ, Robin AL, Walters TR, Barneby HS, Choplin N, Kelley EP, Stoecker JF. Brimonidine tartrate: a one month dose response study. Ophthalmology 1997, 104:131-136.
10. Araujo SV, Bond JB, Wilson RP, et al.: Long-term effect of apraclonidine. Br J Ophthalmol 1995, 79:1098-1101.
11. Jampel HD, et al.: Apraclonidine: a one week dose-response study. Arch Ophthalmol 1988, 106:1069.
12. Rosenthal AL, Walters T, Berg E, et al. : A comparison of the safety and efficacy of brimonidine 0.2% BID versus TID in subjects with elevated intraocular pressure [abstract]. Invest Ophthalmol Vis Sci 1996, 37(S):S831.
13. Schuman JS, Horwitz B, Choplin NT, et al.: A one-year study of brimonidine twice daily in glaucoma and ocular hypertension. Arch Ophthalmol 1997, 115:847-852.
14. Chien D-S, Homsy JJ, Gluchowski C, Tang-Liu D-S: Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr Eye Res 1990, 9:1051-1059.
15. Jeon YT, Luo C, Forray C, Vaysse P J-J, Branchek TA, Gluchowski C: Pharmacological evaluation of UK-14,304 analogs at cloned human α adrenergic receptors. Bioorg Med Chem Lett 1995, 5:2255-2258.
16. Rouot BR, Snyder SH: [3H] Para-amino-clonidine: a novel ligand which binds with high affinity to α-adrenergic receptors. Life Sci 1979, 25:769-774.
17. Burke J, Kharlamb A, Shan T, Runde E, Padillo E, Manlapaz C, Wheeler L: Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys: a species difference. Ann NYAcad Sci 1995, 763:78-95.
18. 2-Adrenergic Receptors: Structure, Function and Therapeutic Implications. Edited by Lanier S, Limbird L. The Netherlands: Harwood Academic Publishers; 1996: 179-187.
19. Gluchowski C, Jeon YT, Wetzel JM, Vaysse PJ-J, Branchek TA, Weishank RL, Borden LA, Bard JA, Hartig PR: Use of recombinant human alpha-adrenergic receptors for the pharmacological evaluation of alpha-adrenergic ocular hypotensive agents. Invest Ophthalmol Vis Sci 1994, 35:1399.
20. Emsberger P, Giuliano R, Willette RN, Reis DJ: Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990, 253:408.
21. DeJonge A, Timmermans PBMWM, van Zwieten PA: Quantitative aspects of alpha-adrenergic effects induced by clonidine-like imidazolidines: I. Central hypotensive and peripheral hyptertensive activities. J Pharmacol Exp Therap 1982, 222:705-711.
22. Zhan GL, Toris CB, Gaffney MM, Durrett SP, Tons AJ, Camras CB, Yablonski ME: Effects of apraclonidine and brimonidine on rabbit ocular blood flow. Invest Ophthalmol Vis Sci 1997, 38:5783.
23. 2-Adrenergic Receptors: Structure, Function and Therapeutic Implications. Edited by Lanier S, Limbird L. The Netherlands: Harwood Academic Publishers: 1996.
24. Lung MA: Mechanisms of sympathetic enhancement and inhibition of parasympathetically induced salivary secretion in anesthetized dogs. Br J Pharmacol 1994, 112:411-416.